Log in

NASDAQ:DXR - Daxor Stock Price, Forecast & News

$9.56
-0.04 (-0.42 %)
(As of 02/17/2020 07:01 AM ET)
Today's Range
$9.22
Now: $9.56
$9.56
50-Day Range
$9.01
MA: $9.50
$9.86
52-Week Range
$7.13
Now: $9.56
$19.95
Volume1,220 shs
Average Volume1,729 shs
Market Capitalization$35.82 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DXR
CUSIPN/A
CIKN/A
Phone212-330-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$35.82 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.


Daxor (NASDAQ:DXR) Frequently Asked Questions

What is Daxor's stock symbol?

Daxor trades on the NASDAQ under the ticker symbol "DXR."

What is the consensus analysts' recommendation for Daxor?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Daxor.

Has Daxor been receiving favorable news coverage?

Media headlines about DXR stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Daxor earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Daxor.

Who are some of Daxor's key competitors?

Who are Daxor's key executives?

Daxor's management team includes the folowing people:
  • Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)
  • Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)
  • Mr. Robert J. Michel M.B.A., CPA, CPA, CFO, Chief Compliance Officer & Corp. Sec. (Age 62)
  • Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
  • Mr. Guido Manzo, VP of Sales

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Daxor's stock price today?

One share of DXR stock can currently be purchased for approximately $9.56.

How big of a company is Daxor?

Daxor has a market capitalization of $35.82 million. View Additional Information About Daxor.

What is Daxor's official website?

The official website for Daxor is http://www.daxor.com/.

How can I contact Daxor?

The company can be reached via phone at 212-330-8500.


MarketBeat Community Rating for Daxor (NASDAQ DXR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about Daxor and other stocks. Vote "Outperform" if you believe DXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel